Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice.

PubWeight™: 1.96‹?› | Rank: Top 2%

🔗 View Article (PMC 2363131)

Published in Br J Cancer on August 01, 1999

Authors

A Ravaud1, C Bedane, L Geoffrois, T Lesimple, M Delaunay

Author Affiliations

1: Department of Medicine, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Articles citing this

Adjuvant interferon in the treatment of melanoma. Br J Cancer (1999) 1.39

Measuring sickness behavior in the context of pancreatic cancer. Med Hypotheses (2015) 0.75

Articles by these authors

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet (1998) 3.84

Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst (2009) 2.83

Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol (1995) 2.37

Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol (1999) 2.34

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer (2004) 1.93

Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol (1998) 1.70

Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer (1997) 1.67

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol (2000) 1.59

A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44

[Does bullous pemphigoid with negative direct immunofluorescence exist? Apropos of 3 cases]. Ann Dermatol Venereol (1992) 1.40

Role of drug exposure in aphthous ulcers: a case-control study. Br J Dermatol (2000) 1.39

Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer (2000) 1.29

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood (2000) 1.27

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res (2003) 1.24

Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol (1989) 1.21

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol (2002) 1.18

Bier's white spots associated with scleroderma renal crisis. Clin Exp Dermatol (2006) 1.17

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol (2007) 1.11

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol (2012) 1.08

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer (2003) 1.05

Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol (1996) 1.04

Aortic angiosarcoma clinically mimicking polyarteritis nodosa. Scand J Rheumatol (2006) 1.02

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer (2007) 0.98

Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int J Cancer (2000) 0.98

[Giant buccal aphthosis caused by nicorandil]. Presse Med (1997) 0.96

Male breast cancer and the androgen receptor gene. Nat Genet (1993) 0.96

Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology (2004) 0.95

Androgen receptor gene mutation in male breast cancer. Hum Mol Genet (1993) 0.94

Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol (2011) 0.92

[Eccrine porocarcinoma: a highly malignant tumor with a poor prognosis]. Ann Dermatol Venereol (2008) 0.91

Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancérologie Cutanée. Eur J Cancer (1998) 0.91

Endoscopic surgery reveals that woodworkers' adenocarcinomas originate in the olfactory cleft. Rhinology (2007) 0.90

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer (2005) 0.90

Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol (2005) 0.90

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol (2003) 0.89

Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol (1996) 0.88

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie. J Clin Oncol (1998) 0.88

[Bacterial dermo-hypodermatitis in adults. Incidence and role of streptococcal etiology]. Ann Dermatol Venereol (1995) 0.88

White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma. Clin Cancer Res (2000) 0.87

Adhesion molecule expression and response to chemotactic agents of human monocyte-derived macrophages. Clin Exp Immunol (1996) 0.87

Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). Eur J Cancer (2004) 0.86

The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol (1999) 0.86

Widespread cutaneous carcinomas associated with human papillomaviruses 5, 14 and 20 after introduction of methotrexate in two long-term PUVA-treated patients. Dermatology (2001) 0.86

Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer (2002) 0.85

Treatment of verrucous carcinoma with recombinant alfa-interferon. Dermatology (1995) 0.85

Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother Pharmacol (1990) 0.85

Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol (2010) 0.84

[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]. Cancer Radiother (2003) 0.84

[Intracystic breast carcinoma. A case report]. J Gynecol Obstet Biol Reprod (Paris) (1998) 0.84

Cervical lymph node metastasis from an unknown primary: is a tonsillectomy necessary? Int J Radiat Oncol Biol Phys (1997) 0.84

Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas. Blood (1999) 0.84

Postoperative interstitial radiotherapy of keloids by iridium 192: a retrospective study of 46 treated scars. Dermatology (1997) 0.83

Management of patients with head and neck tumours presenting at diagnosis with a synchronous second cancer at another anatomic site. Clin Oncol (R Coll Radiol) (2010) 0.83

Internalization of human macrophage surface antigens induced by monoclonal antibodies. J Immunol Methods (1995) 0.83

Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial. Br J Cancer (2001) 0.83

[Methi-resistant Staphylococcus aureus in dermatological practice: origin, risk factors and outcome]. Ann Dermatol Venereol (2002) 0.83

Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma. Eur J Cancer (2001) 0.83

CT assessment of woodworkers' nasal adenocarcinomas confirms the origin in the olfactory cleft. AJNR Am J Neuroradiol (2009) 0.83

[Verrucous carcinoma of the lower limbs]. Ann Dermatol Venereol (2007) 0.82

A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. Gynecol Oncol (1999) 0.82

[Elements of epidemiology and initiation of carcinogenesis in carcinomas of the upper aerodigestive tract. Future therapeutic consequence?]. Rev Laryngol Otol Rhinol (Bord) (1999) 0.82

Relevance of vertical growth pattern in thin level II cutaneous superficial spreading melanomas. Am J Surg Pathol (2003) 0.81

[Primary cutaneous large B-cell lymphoma in chronic venous leg ulcer]. Ann Dermatol Venereol (2007) 0.81

A proliferative vascular tumour of the skin in a kidney-transplant recipient (recurrent pyogenic granuloma with satellitosis). Nephrol Dial Transplant (1997) 0.81

[Pemphigoid vegetans. An immunoelectron microscopic study]. Ann Dermatol Venereol (1997) 0.81

[Survival prognosis in pemphigoid. A cohort analysis of 78 patients]. Ann Dermatol Venereol (1995) 0.81

Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas. J Invest Dermatol (2001) 0.81

Rapidly lethal dermatomyositis associated with metastatic melanoma. J Eur Acad Dermatol Venereol (2008) 0.81

UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. Eur J Cancer (2001) 0.80

[Long term continuous combination of cisplatin and 5 fluorouracil in advanced breast neoplasms. A retrospective study of 77 patients]. Bull Cancer (1993) 0.80

Pilotropic cutaneous T-cell lymphoma without mucinosis. A variant of mycosis fungoides? French Study Group of Cutaneous Lymphomas. Arch Dermatol (1996) 0.80

Thalidomide and recurrent aphthous stomatitis: a follow-up study. Dermatology (1996) 0.80

Studies of cicatricial pemphigoid autoantibodies using direct immunoelectron microscopy and immunoblot analysis. J Invest Dermatol (1990) 0.79

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol (1998) 0.79

[Standards, Options, and Recommendations for the management of brief neutropenias. Fedération Nationale des Centres de Lutte Contre le Cancer]. Bull Cancer (1998) 0.79

A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol (1999) 0.79

Neoadjuvant chemotherapy: a new criterion for selection of candidate patients for surgery of low tumour burden metastases from malignant melanoma? Br J Dermatol (2010) 0.79

[Thyroid metastases from cancer of the kidney. Two cases]. Presse Med (1995) 0.79

Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer (1993) 0.78

[Bullous pemphigoid. Guidelines for the diagnosis and treatment. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie]. Ann Dermatol Venereol (2011) 0.78

Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur Cytokine Netw (2000) 0.78

[Merkel cell carcinoma: outcome and role of radiotherapy]. Cancer Radiother (2008) 0.78

Cardiomyopathy after acute myocardial infarction after therapy with interleukin-2 and tumour infiltrating lymphocytes. Eur J Cancer (1992) 0.78

[Prenatal diagnosis of hereditary bullous epidermolysis. A case report]. J Gynecol Obstet Biol Reprod (Paris) (1996) 0.78

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer (2012) 0.78

Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment. Br J Dermatol (2002) 0.78

[Intra-epidermal neutrophilic IgA dermatosis associated with IgA myeloma]. Ann Dermatol Venereol (1990) 0.77

Acquired ichthyosis with pravastatin. J Eur Acad Dermatol Venereol (2007) 0.77

[Sentinel lymph node biopsy for lymphophilic conjunctival and eyelid tumors: report of 8 cases]. Rev Laryngol Otol Rhinol (Bord) (2009) 0.77

[Standards, Options and Recommendations (SOR) for the surveillance and the prevention of cross infections in oncology. Fédération Nationale des Centres de Lutte Contre le Cancer]. Bull Cancer (2000) 0.77

In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates. Int J Cancer (2000) 0.77

Impact of clinical practice guidelines on the management for carcinomas of unknown primary site: a controlled "before-after" study. Bull Cancer (2009) 0.77

[Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study]. Bull Cancer (1990) 0.77

[Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)]. Ann Dermatol Venereol (2003) 0.77

[Photodynamic therapy for the treatment of extramammary Paget's disease]. Ann Dermatol Venereol (2011) 0.77

Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol (1997) 0.77

[Cutaneous reactions to gold salts]. Ann Dermatol Venereol (1994) 0.76

Bullous lichen sclerosus with chronic hepatitis C virus infection. Br J Dermatol (1997) 0.76

[Serum S100B protein and stage of cutaneous melanoma: a prospective study]. Ann Dermatol Venereol (2000) 0.76